Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer
Open Access
- 1 September 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 17 (9) , 2480-2487
- https://doi.org/10.1158/1055-9965.epi-08-0150
Abstract
Objective: To evaluate if serum levels of candidate ovarian cancer biomarkers vary with individual characteristics of healthy women who are likely candidates for an ovarian cancer screening program. Methods: We analyzed serum CA125, mesothelin, and HE4 levels in a sample of 155 healthy postmenopausal women at increased risk for developing ovarian cancer based on personal and family cancer history. Information on reproductive, family and medical histories, lifestyle factors, and anthropometry was collected by self-report. Twenty-two factors were examined using univariate and multiple linear regression models for the three biomarker levels. Results: In the multivariate models, CA125 levels were significantly higher in women who had used talcum powder (P = 0.02) and were lower in women who were parous (P = 0.05). Mesothelin levels were significantly higher in older women (P = 0.01) and lower in heavier women (P = 0.03). HE4 levels were higher in older women (P = 0.001) and in women who began menstruating at an older age (P = 0.03). Conclusions: CA125, mesothelin, and HE4 levels in healthy, postmenopausal women at increased risk for ovarian cancer are significantly associated with a few ovarian cancer risk factors. Since the effects of these personal characteristics on these serum markers are not large, their incorporation in screening algorithms may be unnecessary. This is true especially if a longitudinal algorithm is used because the marker level at the previous screen reflects personal characteristics such as age, body mass index, and age of menarche. Understanding the influence of personal factors on levels of novel early detection markers in healthy, unaffected women may have clinical utility in interpreting biomarker levels. (Cancer Epidemiol Biomarkers Prev 2008;17(9):2480–7)Keywords
This publication has 28 references indexed in Scilit:
- Use of Yeast-SecretedIn vivoBiotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISAClinical Cancer Research, 2008
- Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcomeAnnals of Oncology, 2007
- Method for generation of in vivo biotinylated recombinant antibodies by yeast matingJournal of Immunological Methods, 2006
- Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic MarkerCancer Epidemiology, Biomarkers & Prevention, 2006
- Bead-Based ELISA for Validation of Ovarian Cancer Early Detection MarkersClinical Cancer Research, 2006
- New tumor markers: CA125 and beyondInternational Journal of Gynecologic Cancer, 2005
- Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian CarcinomasCancer Research, 2005
- Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinomaGynecologic Oncology, 2004
- Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening MarkerAmerican Journal of Epidemiology, 2004
- A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarkerBiostatistics, 2003